TAF1 plays a critical role in AML1-ETO driven leukemogenesis.
Ye XuNa ManDaniel KarlConcepcion MartinezFan LiuJun SunCamilo Jose MartinezGloria Mas MartinFelipe Cesar BeckedorffFan LaiJingyin YueAlejandro RoismanSarah GreenblattStephanie DuffortLan WangXiao-Jian SunMaria FigueroaRamin ShiekhattarStephen NimerPublished in: Nature communications (2019)
AML1-ETO (AE) is a fusion transcription factor, generated by the t(8;21) translocation, that functions as a leukemia promoting oncogene. Here, we demonstrate that TATA-Box Binding Protein Associated Factor 1 (TAF1) associates with K43 acetylated AE and this association plays a pivotal role in the proliferation of AE-expressing acute myeloid leukemia (AML) cells. ChIP-sequencing indicates significant overlap of the TAF1 and AE binding sites. Knockdown of TAF1 alters the association of AE with chromatin, affecting of the expression of genes that are activated or repressed by AE. Furthermore, TAF1 is required for leukemic cell self-renewal and its reduction promotes the differentiation and apoptosis of AE+ AML cells, thereby impairing AE driven leukemogenesis. Together, our findings reveal a role of TAF1 in leukemogenesis and identify TAF1 as a potential therapeutic target for AE-expressing leukemia.
Keyphrases
- acute myeloid leukemia
- transcription factor
- allogeneic hematopoietic stem cell transplantation
- binding protein
- cell cycle arrest
- induced apoptosis
- single cell
- endoplasmic reticulum stress
- genome wide
- poor prognosis
- cell death
- gene expression
- oxidative stress
- bone marrow
- stem cells
- long non coding rna
- genome wide identification